Aceclofenac

證據等級: L5

預測適應症: 10 個

ACECLOFENAC: Drug Repurposing Evaluation — Preliminary Assessment

One-Sentence Summary

Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) of the phenylacetic acid class, widely used internationally for pain and inflammation management in musculoskeletal conditions. The TxGNN model has not yet generated predicted new indications for this compound, and no clinical trial or literature evidence has been collected at this stage.

Quick Overview

Item	Content
Drug Name (INN)	Aceclofenac
DrugBank ID	DB06736
Original Indication	Not available in current evidence pack (known NSAID for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis)
Predicted New Indication	— (No TxGNN prediction available)
TxGNN Prediction Score	—
Evidence Level	L5 — Model prediction pending; no supporting studies collected
Taiwan Market Status	✗ Not marketed
Number of TFDA Licenses	0
Recommended Decision	Hold

Why is This Drug Being Evaluated?

Aceclofenac (CAS 89796-99-6) is a second-generation NSAID and a prodrug of diclofenac. It preferentially inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby exerting anti-inflammatory, analgesic, and antipyretic effects. It is marketed in numerous countries across Europe, Asia, and Latin America for the management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Currently, detailed mechanism of action data was not returned from the evidence pack sources. Based on established pharmacological knowledge, aceclofenac's COX-2-preferential inhibition profile and its metabolic conversion to diclofenac provide a well-characterized mechanism. This NSAID mechanism could theoretically be relevant to inflammatory-driven conditions beyond musculoskeletal disease, but no TxGNN predictions have been generated at this time to guide exploration of specific new indications.

Clinical Trial Evidence

Currently no predicted indication has been generated, and therefore no related clinical trials have been collected.

Literature Evidence

Currently no predicted indication has been generated, and therefore no related literature has been collected.

Taiwan (TFDA) Market Information

Aceclofenac currently holds no valid TFDA marketing authorizations in Taiwan. The drug is classified as not marketed in the Taiwanese market.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available from the queried sources for the Taiwan market.

General NSAID class warnings (based on established pharmacology) include:

Cardiovascular thrombotic risk with prolonged use

Gastrointestinal bleeding, ulceration, and perforation risk

Renal function impairment, especially in patients with pre-existing renal disease

Contraindicated in patients with known hypersensitivity to aceclofenac, aspirin, or other NSAIDs

Caution in patients with asthma, hepatic impairment, or coagulation disorders

These are general class-level considerations and do not replace product-specific labelling.

Data Gaps Identified

The following critical data gaps were flagged during evidence collection:

Gap ID	Category	Item	Severity	Impact	Remediation
DG001	Drug Level	TFDA Package Insert Warnings / Contraindications	Blocking	Cannot enter S1 safety screening	Download and parse package insert PDF from TFDA website
DG002	Drug Level	Mechanism of Action (MOA)	High	Affects mechanistic relevance analysis	Query DrugBank API for full MOA data

Additionally:

No TxGNN predictions have been generated for this drug — the predicted_indications array is empty
No DDI data was found in the queried sources
No TFDA licenses exist, meaning Taiwan-specific prescribing information is unavailable

Conclusion and Next Steps

Decision: Hold

Rationale: Aceclofenac cannot proceed through the drug repurposing evaluation pipeline at this time. The TxGNN model has not generated any predicted new indications, and multiple blocking data gaps remain unresolved — most critically, the absence of TFDA safety labelling data (DG001) which prevents entry into the S1 safety screening stage.

To proceed, the following is needed:

Run TxGNN prediction for Aceclofenac (DB06736) to generate candidate new indications with confidence scores
Resolve DG001 — Obtain TFDA package insert warnings and contraindications (or confirm no Taiwan-marketed product exists, and source equivalent data from EMA/MHRA/TGA)
Resolve DG002 — Retrieve full MOA data from DrugBank API to enable mechanistic relevance analysis
Collect clinical trial and literature evidence once a predicted indication is available
Reassess Taiwan regulatory pathway — Since Aceclofenac is not marketed in Taiwan, any repurposing effort would require either a new drug application or a special import pathway

This report was generated on 2026-04-03 based on Evidence Pack v4 (candidate ID: TW-DB06736-multi). Results are for research reference only and do not constitute medical advice. Drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.